drugset / Trial / NCT04203641
L-DOS47 Plus Doxorubicin in Advanced Pancreatic Cancer
NaSequentialOpen-labelTreatment
Summary
This study will evaluate the safety and tolerability of escalating doses of L-DOS47 in combination with doxorubicin, as well as preliminary anti-tumor activity in patients with previously treated advanced pancreatic cancer.
Timeline
- Start
- 2019-12-11
- Primary completion
- 2024-10-24
- Completion
- 2024-10-24
Outcome
Outcome not reported
Stopped: “The primary reason for early termination was budget constraint.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | L-DOS47 | Other / unclassified | 3 ug/kg | — |
| Subject | L-DOS47 | Other / unclassified | 6 ug/kg | — |
| Subject | L-DOS47 | Other / unclassified | 9 ug/kg | — |
| Background | Doxorubicin | Other / unclassified | 20 mg/m2 | Intravenous |